News

Seahorse Bioscience has provided update on its XF96 Extracellular Flux Analyzer, used for measuring cellular bioenergetics. The company said that a panel of scientific experts assembled by ‘TheScientist’

Echo Therapeutics has provided updates on the development of its needle-free Prelude SkinPrep System for transdermal drug delivery. The company is developing it as a platform technology for

Pfizer has discontinued A4021016 (also known as ADVIGO 1016), a phase 3 trial examining the effects of investigational compound, Figitumumab (CP-751,871), due to the study meeting predefined boundaries

Cleveland BioLabs (CBLI) has entered into a 50/50 joint venture with Bioprocess Capital Ventures to develop the company’s Curaxin compounds for cancer applications. As per the agreement, CBLI

Bionovo has published results from its study on the anti-tumor mechanism of BN107. The results, published in the International Journal of Cancer, describe the potential molecular mechanisms mediating

QLT has acquired OT-730 from Othera Pharmaceuticals and its wholly-owned subsidiary, Othera Holding, (together, Othera) for a one-time payment of $7.5m in cash. OT-730 is a prodrug of

Clear One Health Plans (Clear One) and PacificSource Health Plans (PacificSource) have signed an agreement under which PacificSource is expected to acquire Clear One. Under the terms of

The FDA has not yet completed its review of Pfizer’s Biologics License Application (BLA) for Prevnar 13, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the company’s candidate 13-valent

The FDA has informed Photocure that the new drug application (NDA) for Hexvix, for detection of non-invasive papillary bladder cancer, may be approved, pending approval of the PMA